

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

Appointment of Chief Operating Officer

This announcement is made by TransThera Sciences (Nanjing), Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The Company announces that Mr. Sun Delong (“**Mr. Sun**”) has been appointed by the board of directors of the Company as the Chief Operating Officer of the Company, with effect from 12 June 2026. In his new role, Mr. Sun will be responsible for the overall commercial operations of the Company. Mr. Sun possesses over 20 years of extensive experience in the biopharmaceutical industry, with capabilities to manage the full spectrum of business, from front-line pharmaceutical marketing and academic promotion to overall corporate operations.

Prior to joining the Company, Mr. Sun served as the chief operating officer of Jiangsu Simcere Medical Diagnostics Co., Ltd. (江蘇先聲醫學診斷有限公司) from June 2023 to February 2026, and was responsible for the comprehensive management of the company. From December 2021 to May 2023, he served as the deputy general manager of Liaoning Herbex Pharmaceutical (Group) Co., Ltd. (遼寧上藥好護士藥業(集團)有限公司) and the general manager of Liaoning Herbex Group Pharmaceutical Co., Ltd. (遼寧好護士集團醫藥有限公司), responsible for the overall management and operations of such companies. From July 2006 to December 2021, Mr. Sun worked at Jiangsu Simcere Pharmaceutical Co., Ltd. (江蘇先聲藥業有限公司), where he successively served as the regional manager of Northeast China, head of national sales, executive director of the group and general manager of the Beijing branch; among which, he served as the executive director of the group from 2017 to December 2021. Mr. Sun holds a bachelor's degree in pharmacy from Shenyang Pharmaceutical University.

The Board would like to express its warmest welcome to Mr. Sun on his appointment.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 12 June 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.